{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T12:14:45Z","timestamp":1782821685522,"version":"3.54.5"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Optimal conditioning regimen for pediatric myeloid malignancies is still subject for debate. This single-center retrospective study compares the efficacy and toxicity profiles of three conditioning strategies, myeloablative conditioning (MAC), reduced-toxicity conditioning (RTC), and reduced-intensity conditioning (RIC), in 59 pediatric patients with myeloid malignancies undergoing allogeneic hematopoietic stem cell transplantation (HSCT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Primary objectives evaluated graft versus host disease (GvHD), relapse, overall survival (OS), disease-free survival (DFS), and mortality causes. Secondary endpoints assessed early complications such as mucositis, engraftment kinetics, viral reactivation, and hospitalization duration. A subgroup analysis compared fludarabine- and clofarabine-based RTC regimens.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>RTC was associated with significantly lower transfusion needs, faster platelet engraftment and shorter hospitalization. Viral reactivations were more common in RTC and RIC, yet viral control, particularly CMV clearance, seemed more effective in RTC. While one-year OS and DFS were generally comparable across regimens, RTC showed a numerically higher OS, with a possible negative influence on relapse rate for children under 10 years old. Severe acute GvHD was similar across groups, but chronic GvHD tended to occur more frequently in RIC. CR status  appeared to influence relapse and mortality patterns, with AML patients transplanted in CR1 experiencing significantly better OS and DFS. Subgroup analysis within RTC (clofarabine vs. fludarabine) revealed promising trends toward improved OS, lower acute GvHD, and reduced relapse-related mortality when using clofarabine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussions<\/jats:title><jats:p>These findings support the use of individualized conditioning strategies in pediatric myeloid malignancies, with RTC emerging as a potentially balanced approach for selected cases.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1623636","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:38:28Z","timestamp":1756903108000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Conditioning regimens in pediatric myeloid malignancies undergoing allogeneic HSCT: a comparative single-center study"],"prefix":"10.3389","volume":"15","author":[{"given":"Andra D.","family":"Marcu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina G.","family":"Jercan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Bica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea N.","family":"Serbanica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letitia E.","family":"Radu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Avramescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anda","family":"Mocanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana O.","family":"Niculita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia C.","family":"Popa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cerasela","family":"Jardan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Dragomir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Colita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina D.","family":"Tanase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Colita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-535716","article-title":"Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens","volume":"123","author":"Bitan","year":"2014","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"B4","first-page":"88","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues (IARC WHO classification of tumours)","author":"Swerdlow","year":"2008"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.2.406","article-title":"Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse","volume":"100","author":"Lee","year":"2002","journal-title":"Blood"},{"key":"B7","article-title":"1994 Consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30256-X","article-title":"Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological Malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"7","author":"Penack","year":"2020","journal-title":"Lancet Haematol"},{"key":"B9","first-page":"840 p","author":"Sureda","year":"2024","journal-title":"The EBMT Handbook"},{"key":"B10","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1038\/bmt.2012.282","article-title":"Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation","author":"Iacobelli","year":"2013","journal-title":"Bone Marrow Transpl"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.12.489","article-title":"Busulfan in hematopoietic stem cell transplantation","volume":"15","author":"Ciurea","year":"2009","journal-title":"Biol Blood Marrow Transpl"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01201-w","article-title":"Hematopoietic cell transplant in pediatric acute myeloid leukemia after similar upfront therapy; a comparison of conditioning regimens","volume":"56","author":"Versluys","year":"2021","journal-title":"Bone Marrow Transpl"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.11.027","article-title":"Fludarabine and exposure-targeted busulfan compares favorably with busulfan\/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity","volume":"20","author":"Bartelink","year":"2014","journal-title":"Biol Blood Marrow Transpl"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.204","article-title":"CY and melphalan for children with AML in second CR","volume":"48","author":"Beier","year":"2013","journal-title":"Bone Marrow Transpl"},{"key":"B15","article-title":"Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes","volume":"8","author":"Locatelli","year":"1994","journal-title":"Leukemia"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.11.022","article-title":"Impact of conditioning regimen on outcomes for children with acute myeloid leukemia undergoing transplantation in first complete remission. An analysis on behalf of the pediatric disease working party of the European group for blood and marrow transplantation","volume":"23","author":"Lucchini","year":"2017","journal-title":"Biol Blood Marrow Transpl"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0584-8","article-title":"Hematopoietic stem cell transplantation for children with acute myeloid leukemia\u2014results of the AML SCT-BFM 2007 trial","volume":"34","author":"Sauer","year":"2020","journal-title":"Leukemia"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13158","article-title":"Transplant-related mortality and survival in children with Malignancies treated with allogeneic hematopoietic stem cell transplantation. A multicenter analysis","volume":"22","author":"Zaucha-Prazmo","year":"2018","journal-title":"Pediatr Transpl"},{"key":"B19","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1182\/blood-2023-188868","article-title":"Fludarabine and melphalan reduced toxicity versus a myeloablative fludarabine and busulfan conditioning regimen for acute myeloid leukemia","volume":"142","author":"Mathews","year":"2023","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018016956","article-title":"Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine","volume":"2","author":"Harris","year":"2018","journal-title":"Blood Adv"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2011.242","article-title":"Allogeneic hematopoietic SCT in patients with AML following treosulfan\/fludarabine conditioning","volume":"47","author":"Casper","year":"2012","journal-title":"Bone Marrow Transpl"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.4","article-title":"Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity","volume":"47","author":"Shimoni","year":"2012","journal-title":"Bone Marrow Transpl"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25764","article-title":"European society for blood and marrow transplantation analysis of treosulfan conditioning before hematopoietic stem cell transplantation in children and adolescents with hematological Malignancies","volume":"63","author":"Boztug","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.11.023","article-title":"Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplantation","volume":"23","author":"Sakellari","year":"2017","journal-title":"Biol Blood Marrow Transpl"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.09.014","article-title":"The incidence and severity of oral mucositis among allogeneic hematopoietic stem cell transplantation patients: A systematic review","volume":"22","author":"Chaudhry","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04568-y","article-title":"Oral mucositis in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation in relation to the conditioning used prior to transplantation","volume":"100","author":"Wysocka-Slowik","year":"2021","journal-title":"Ann Hematol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702447","article-title":"Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological Malignancy: an overview","volume":"25","author":"Blijlevens","year":"2000","journal-title":"Bone Marrow Transpl"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01896-z","article-title":"The incidence and impact of clostridioides difficile infection on transplant outcomes in acute leukemia and MDS after allogeneic hematopoietic cell transplant-a CIBMTR study","volume":"58","author":"Ramanathan","year":"2023","journal-title":"Bone Marrow Transpl"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000000662","article-title":"Risk for clostridium difficile infection after allogeneic hematopoietic cell transplant remains elevated in the postengraftment period","volume":"3","author":"Dubberke","year":"2017","journal-title":"Transplant Direct"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.09.021","article-title":"Biologically randomized comparison of haploidentical versus human leukocyte antigen-matched related donor reduced-intensity conditioning hematopoietic cell transplantation","volume":"30","author":"Grunwald","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.02.010","article-title":"Haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide in children with high-risk leukemia using a reduced-intensity conditioning regimen and peripheral blood as the stem cell source","volume":"27","author":"Trujillo","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1172\/JCI124218","article-title":"Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression","volume":"129","author":"Wachsmuth","year":"2019","journal-title":"J Clin Invest"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13040827","article-title":"Insights into pediatric GATA2-related MDS: unveiling challenges in clinical practice","volume":"13","author":"Marcu","year":"2025","journal-title":"Biomedicines"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-020-01386-6","article-title":"Myeloablative versus reduced intensity conditioning regimens for allogeneic hematopoietic stem cell transplant for acute myeloid leukemia and myelodysplastic syndrome: A retrospective analysis","volume":"37","author":"Sharma","year":"2021","journal-title":"Indian J Hematol Blood Transfus"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.159343","article-title":"Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis","volume":"102","author":"Buckley","year":"2017","journal-title":"Haematologica"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2011.69","article-title":"Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS","volume":"47","author":"Luger","year":"2012","journal-title":"Bone Marrow Transpl"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1182\/blood-2023-184520","article-title":"Allogeneic stem cell transplantation with myeloablative compared with reduced- intensity conditioning for AML and Mds; 20 years later","volume":"142","author":"Shimoni","year":"2023","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2015.04.009","article-title":"Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"39","author":"Kharfan-Dabaja","year":"2015","journal-title":"Leuk Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1623636\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:38:30Z","timestamp":1756903110000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1623636\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":39,"alternative-id":["10.3389\/fonc.2025.1623636"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1623636","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,3]]},"article-number":"1623636"}}